|
|
379 Oyster Point Boulevard, Suite 10
South San Fransisco, CA 94080 USA
phone:(650) 624-2439
fax:(650) 624-4785
|
|
| Symbol |
VXGN |
| Exchange |
OTCBB |
| Founded |
0 |
| Employees |
117 |
|
|
| www.vaxgen.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Products for the prevention and treatment of human infectious disease. |
|
| Management |
| James P. Panek, President and Chief Executive Officer and Principal Accounting Officer; Piers Whitehead, Vice President, Corporate and Business Development and Company Secretary; |
| |
|
|
|
|
|
|
|
| Keywords |
| anthrax, smallpox, recombinant technology, infectious disease, InfectiousDisease |
|
|
|
| Description |
|
VaxGen Inc. is a biopharmaceutical company focused on the commercial development and manufacture of products for the prevention and treatment of human infectious disease. Spun-out of Genentech in 1995, the Company utilizes recombinant technology to clone and express complex proteins, including those made through bacterial and mammalian-cell fermentation. It is focused on developing and commercializing vaccine candidates to address bioterrorism threats, including anthrax and smallpox. VaxGen is funded by the National Institutes of Health (NIH) to develop a modern, recombinant anthrax vaccine, known as rPA102. In October 2003, it was awarded a contract from the NIH to advance the vaccine candidate into Phase II clinical trials, conduct animal efficacy studies and manufacture a three-million-dose stockpile of rPA102. The Company is the single-largest shareholder in Celltrion Inc., a joint venture formed to build biopharmaceutical manufacturing operations. |
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
